mark status. This means that INIFY(®) Prostate Screening is now available for
routine clinical use within the European Union.
“I am proud of the great performance by our outstanding multidisciplinary team
in reaching this company milestone. Healthcare systems around the world are
already under great stress due to heavy workloads and lack of resources - and
both patient numbers and cancer rates are only increasing. Intelligent
technology will be a vital key to addressing these challenges, with powerful
tools supporting the medical professionals in terms of efficiency and
precision,” says Fredrik Palm, CEO at ContextVision.
“We are a first mover in what I am certain will become a billion-dollar market.”
ContextVision is an independent world-wide leader within digital image
enhancement for multiple imaging modalities. With its 35-year history of
developing advanced software for digital image analysis and enhancement, it was
a natural step forward to invest in and aim for a leading position within
clinical pathology - a discipline where today’s ongoing digitalization offers
INIFY(®) Prostate Screening is a powerful AI-based software that predicts,
outlines and quantifies suspected cancerous areas in a series of prostate
biopsies. It pre-sorts slides in a worst-first order, allowing pathologists to
get right to work on the most relevant areas. While the product can be used as a
stand-alone unit, even more importantly it is designed to be seamlessly
integrated into pathology laboratories’ existing LIS (Laboratory Information
Systems) or PACS (Picture Archiving and Communication Systems).
“I can testify that it is really easy to use, saves time and helps highlight
suspicious areas for cancer.”
The predicting engine in INIFY(®) Prostate Screening is built on deep learning
algorithms, trained and adapted by ContextVision’s skilled research scientists,
resulting in proprietary high-performance algorithms with pixel-level accuracy.
Our unique, patented MasterAnnotation™ method has been used to create the
training data on which the engine is built. Here, multiplex immunofluorescent
staining is used to objectively identify and highlight cancer areas and other
structures with extreme precision, which in turn are quality assured by
“We have been involved in the development of INIFY(®) Prostate Screening and can
assure it fits laboratory needs. A prototype version of the product has been
used daily for two years in our fully digital pathology workflow here in
Catania, and I can testify that it is really easy to use, saves time and helps
highlight suspicious areas for cancer,” says Dr. Filippo Fraggetta, chief
pathologist at the Pathology Unit of Cannizzaro Hospital.
ContextVision clearly sees the need for a product that can support the
pathologist in identifying prostate cancer faster and more easily, with the
highest possible precision. INIFY(®) Prostate Screening will facilitate the
transformation of clinical pathology into a digital discipline, ultimately
offering much higher quality and standardization.
“INIFY(®) Prostate Screening will allow pathologists to focus their time on
assessing and examining prostate specimens containing suspicious cancer areas,
while minimizing time spent on benign tissue. Knowing that collaboration with
the medical profession is essential, we have worked closely with multiple
pathology labs around the world, all at the forefront of digitalization. Now,
with our first product available for clinical use within EU, we can expect
several full installations in the clinical workflow this fall. We are a first
mover in what I am certain will become a billion-dollar market,” says Palm.
“Prostate cancer is the second most common cancer in the world among men, with
2.3 million biopsy procedures carried out annually in Europe and the US alone.
With INIFY(®) Prostate Screening, we have laid a solid groundwork - which in
turn can be further adapted to address other cancer types, such as colon and
For further information, please contact ContextVision’s CEO, Fredrik Palm, at
+46 76 870 25 43 or visit www.contextvision.com.
ContextVision is a medical technology software company specialized in image
analysis and artificial intelligence. As the global market leader within image
enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-
ray and MRI equipment around the world.
Our expertise is to develop powerful software products, based on proprietary
technology and artificial intelligence for image-based applications. Our
cutting-edge technology helps clinicians accurately interpret medical images, a
crucial foundation for better diagnosis and treatment.
ContextVision is now entering the fast-growing digital pathology market. We are
re-investing significantly in our product portfolio of decision support tools
and we are dedicated to becoming a leading resource for pathologists to
radically develop cancer diagnosis and improve patient care.
The company, established in 1983, is based in Sweden with local representation
in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock
Exchange under the ticker COV.
This information is information that ContextVision is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, on June
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act